Insights-BioDuro-Global CRDMO, Rooted in Science

From AI-Driven Target Intelligence to Experimental Validation | A Conversation with Olivier Collart, Founder of Intangia

BioDuro’s Integrated Discovery Platform (IDD) helps clients move from target to pre-clinical candidate with speed, rigor, and confidence. At the same time, early discovery clients face a growing challenge: with more publications, patents, clinical trials, company activities, and modality innovations than ever before, how do they decide which opportunities are worth testing? To explore how AI-driven target intelligence can support this process, we sat down with Olivier Collart, Founder of Intangia, to discuss how the platform helps teams identify, prioritize, and validate novel target, indication, and assay opportunities — and how this can complement BioDuro’s discovery capabilities.

June 09, 2026

An Optimal Approach Balances Solubilization with Cost and Scalability

This article, with insights from Hong Li, Ph.D., Vice President of Formulation, BioDuro, was originally published in the Drug Development & Delivery, March/April 2026, pages 37-38.

April 28, 2026

Next Generation of Peptide Drug Discovery: A Conversation on Peptide DNA-Encoded Library Platform

In 1922, 14-year-old Leonard Thompson became the first patient to receive insulin, marking a defining milestone in the emergence of peptide therapeutics. Today, as peptide molecules become increasingly complex, they have evolved from simple natural sequence mimics into highly engineered structures with precise chemical modifications and well-defined three-dimensional structures.

April 14, 2026

Sustaining Client Trust through a Comprehensive Discovery Chemistry Platform | A Conversation with Dr. Li Feng

Building lasting trust with our clients is at the heart of what we do. In 2025, Daewoong Pharmaceutical recognized BioDuro as Best CRO in 2025, a mark of the trust built through years of consistent collaboration. That trust echoed across our global client base: we received such customer recognitions from over 100 clients worldwide. For the chemistry team, about 50% of our FTE clients expanded their engagement, and notably, none shifted work to competing CROs.

March 30, 2026

What You Need to Know About Our Newly Added Commercial API Manufacturing Capacity

About our recently announced joint venture with CENRA API Solutions/CCSB, our President of Global CMC, Mr. Yaohui Ji, shared insights on what this newly added capability means for our customers. It offers a flexible, coordinated approach with unified quality systems, regulatory readiness, and support across small molecules, peptides, and fermentation products, combining technical depth with agility to help programs scale from development to commercial production.

March 17, 2026

Predicting Accurately to De-Risk Early Development

An exposure-driven, translational approach, linking early ADME with biomarker discovery, can help teams define the therapeutic window long before lead candidate nomination, according to Hong Wan from BioDuro.

February 11, 2026

BioDuro Advances DNA-Encoded Peptide Libraries: 108-Channel Automation Enables 10-mer+ DNA-Encoded Macrocycles for High-Throughput Drug Discovery

BioDuro has developed a 108-channel automated solid-phase peptide synthesis system that produces oligopeptide building blocks with approximately 90% crude purity, enabling construction of DNA-encoded libraries featuring 10-mer+ macrocyclic peptides. This capability addresses a critical bottleneck in DEL peptide technology -- the historical limitation to short peptide lengths -- while maintaining compatibility with the split-and-pool synthesis workflow that enables library sizes reaching billions of compounds.

February 08, 2026

Stop Bottlenecks Before They Happen: Early-Stage Drug Development Tips

This article, with insights from Subas Sakya, Chief Scientific Officer, BioDuro, was originally published in the Chimica Oggi-Chemistry Today, Vol. 43(5), pages 71-72.

October 30, 2025